Opus Genetics, INC 8-K filings

Opus Genetics is responding to a Paragraph IV Certification Notice from Sandoz regarding a generic version of RYZUMVI, potentially leading to a patent infringement lawsuit.

Opus Genetics has amended employment agreements for its CEO and CFO, increasing severance payments and extending COBRA coverage upon qualifying terminations, especially in connection with a change in control.

Opus Genetics has scheduled its 2025 Annual Meeting of Stockholders for April 30, 2025, and announced deadlines for stockholder proposals and director nominations.

Opus Genetics initiates an at-the-market equity offering program to sell up to $40 million of its common stock through Leerink Partners.

Opus Genetics, Inc., formerly Ocuphire Pharma, Inc., finalized its acquisition of the former Opus Genetics Inc., and filed an amended 8-K report including pro forma financial information.

Opus Genetics announced its third quarter 2024 financial results, highlighting the acquisition of Opus Genetics by Ocuphire Pharma and a pro forma cash balance of approximately $37 million.

Ocuphire Pharma has acquired Opus Genetics in an all-stock transaction, forming a leading clinical-stage company focused on gene therapy treatments for rare inherited retinal degenerations.

Ocuphire Pharma announced its second quarter 2024 financial results and provided updates on its clinical programs, including the start of patient recruitment for the VEGA-3 Phase 3 trial.

Ocuphire Pharma's stockholders approved an increase in authorized shares and the company adopted amended bylaws to enhance governance procedures.

Ocuphire Pharma's post-hoc analysis of the ZETA-1 trial shows a significant treatment benefit of APX3330 in a high-risk subgroup of patients with non-proliferative diabetic retinopathy (NPDR).

Ocuphire Pharma announced its first quarter 2024 financial results, highlighting progress with APX3330 and the commercial launch of RYZUMVI by partner Viatris.

Ocuphire Pharma has entered into a consulting agreement with board member Jay Pepose, M.D., providing monthly fees, restricted stock units, and stock options.

Ocuphire Pharma is progressing its diabetic retinopathy program with a focus on oral treatment APX3330, supported by positive Phase 2 results and a partnership with Viatris for Ryzumvi.

Ocuphire Pharma announced its financial results for the fourth quarter and full year 2023, highlighting progress in its clinical programs and a recent FDA approval.

Ocuphire Pharma has appointed Nirav Jhaveri as its new Chief Financial Officer, effective February 12, 2024.